Summary

Overview
Global arthralgia treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Arthralgia is also known as joint pain. It can affect any joint in the body, including the hips, shoulders, elbows, wrists, hands, knees, ankles, and feet. Many different diseases and conditions can cause arthralgia, including arthritis, bursitis, tendinitis, overuse injuries, gout, and other inflammatory conditions. Especially, arthralgias may be caused due to side effects of certain cancer chemotreatments and medications such as paclitaxel, bleomycin, cladribine, and L-asparaginase as well as biological response modifiers
Further, the treatment of arthralgia includes NSAIDs like ibuprofen, naproxen, or indomethacin, antibiotics, analgesics, disease-modifying antirheumatic drugs (DMARDs), corticosteroids, hyaluronic acid substitutes and nutritional supplements like Calcium and Vitamin D supplements are used to prevent bone loss and Allopurinol is an enzyme inhibitor and other treatments. Alternative exercise therapies include water therapy and heat and cold fomentation therapy is also considered.
Market Dynamics: Drivers
Increasing demand for novel therapeutics
The increasing demand for novel therapeutics for the treatment of arthralgia is expected to drive the market over the forecast period. There is an increasing preference for non-invasive and non-pharmacological treatments for arthralgia, such as biologic therapies, physical therapy, and lifestyle interventions. This preference contributes to the demand for novel therapeutic options that provide effective relief with fewer side effects.
For instance, in March 2022, CV Sciences introduced a new product to its Wellness line of CBD products called +PlusCBD Relief Softgels used for the treatment of osteoarthritis or arthralgia. According to CV Sciences, the product delivers seven times more CBDA and CBD than the original +PlusCBD raw formula and also features Levagen+ PEA (palmitoylethanolamide), which has the ability to influence the endocannabinoid system and has been shown in research to be similarly effective to NSAIDs, such as ibuprofen.
Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in arthralgia treatment. Advances in pharmaceutical research and development, including the discovery of new molecules and targeted therapies, are driving the development of novel therapeutics for arthralgia. These advancements offer more effective and specific treatment options.
For instance, in December 2022, Lupin Ltd. launched an authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution) 2 percent w/w of Horizon Pharma Therapeutics in the United States. PENNSAID (diclofenac sodium topical solution) is used for the treatment of inflammatory diseases like gout, arthralgia and osteoarthritis to relieve pain in the knee and other joints.
In addition, the regulatory approvals increase the trust in patients about the development of novel therapeutics. Collaborations between pharmaceutical companies and technology firms result in the integration of artificial intelligence and machine learning in drug discovery and development. This collaboration-driven innovation brings about novel therapeutics with enhanced effectiveness and efficiency.
Further, the increasing prevalence of arthralgia myositis, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements in the treatment options and therapies are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications and the side effects associated with NSAIDs and other drugs, the high cost of the treatment, increasing competition from generic drugs and availability of alternative treatment options are expected to hamper the market.
Segment Analysis
The global arthralgia treatment market is segmented based on treatment type, distribution channel and region.
The non-steroidal anti-inflammatory drugs (NSAIDs) segment accounted for approximately 48.2% of the arthralgia treatment market share
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold the largest market share over the forecast period. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, aspirin or naproxen and others are most commonly used and may help relieve pain and swelling for arthralgia patients. NSAIDs are drugs known to provide effective pain relief by inhibiting the production of prostaglandins, which are substances in the body that contribute to pain and inflammation.
Moreover, these drugs are available both over-the-counter (OTC) and by prescription. NSAIDs come in various formulations, including oral tablets, capsules, topical creams or gels, and injectable forms, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In addition, their wide adoption also increases the demand for the NSAIDs.
Geographical Analysis
North America accounted for approximately 39.7% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. The presence of major players involves performing research activities to develop more advanced treatment options and alternative treatment options for arthralgia.
For instance, on June 26, 2023, Genesys Spine launched the SIros O Oblique SI Fusion system. This is the third sacroiliac joint fusion system offered by Genesys Spine and provides physicians with expanded surgical options to address SI Joint pain.
Moreover, the region is also known for its advanced healthcare facilities using advanced treatment options. The advanced healthcare infrastructure in the region including hospitals, specialty clinics, academic and research institutes and others, this presence of advanced healthcare infrastructure helps to provide advanced treatment facilities for the treatment of arthralgia. Even many FDA approvals are going on in the region for many advanced devices and other therapeutics.
For instance, in July 2023, Medical technology company Motive Health officially introduced Motive Knee, its US Food and Drug Administration (FDA)-approved stimulation device. The knee pain relief device was previously available on a prescription but it can now be ordered by customers without a prescription. Motive Knee has been clinically validated to alleviate knee discomfort and improve mobility by strengthening the knee by leveraging stimulation technology.
Competitive Landscape
The major global players in the arthralgia treatment market include Mallinckrodt plc, BASF Corporation, GlaxoSmithKline plc, KD Pharma Group SA, Teva Pharmaceuticals USA, Inc., LGM Pharma, Elam Pharma Pvt. Ltd., Amar Healthcare, Bayer AG and Mayne Pharma Group Limited among others.
Key Developments
• On July 11, 2023, Kneeflow utilized a 3-in-1 therapy method with soft massage airbags, infrared light and heat to provide deeper penetration into joints, cartilage and tissue for more effective pain relief, recovery and increased mobility in 10–15-minute sessions. Kneeflow is an at-home, personalized massaging device that can help with the recovery process, prevention and joint pain relief.
• On July 16, 2021, GSK Consumer Healthcare launched the Iodex Rapid Action Spray, a body pain relief solution for modern-day consumers. Iodex now has an exhaustive portfolio of pain relief products such as Iodex Balm, Iodex UltraGel & Iodex Rapid Action Spray, which can cater to different pain states & address varied format preferences of consumers. It has a formula of five active ingredients, namely Indian Wintergreen Oil, Menthol, Eucalyptus oil, Turpentine oil and Clove oil. The blend of ingredients with known analgesic properties helps provide targeted relief from different types of joint pains.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global arthralgia treatment market. Many clinical trials and research activities for new arthralgia treatments or therapies may have been delayed or temporarily disrupted due to the redirected focus on the COVID-19 pandemic and its related restrictions. This can affect the timelines for the introduction of novel treatments to the market. The pandemic also disrupted the supply chain of these treatment drugs globally.
Why Purchase the Report?
• To visualize the global arthralgia treatment market segmentation based on treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of arthralgia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global arthralgia treatment market report would provide approximately 53 tables, 50 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents